Product Description
Dutasteride 164656-23-9
AI Product Description
*The following content is generated by AI and is for reference only.
Dutasteride is a potent synthetic 4-azasteroid compound primarily utilized in the treatment of benign prostatic hyperplasia (BPH) and off-label for androgenetic alopecia. Chemically, it functions as a dual inhibitor of both type I and type II 5-alpha-reductase enzymes. These enzymes are responsible for converting testosterone into dihydrotestosterone (DHT), a more potent androgen that drives prostate enlargement and hair follicle miniaturization. By blocking this conversion pathway, Dutasteride significantly lowers serum and tissue DHT levels, thereby reducing prostate volume and improving urinary flow symptoms in men with BPH.
The molecular formula of Dutasteride is C28H42N2O4, reflecting its complex steroid backbone modified with specific functional groups to enhance enzyme binding affinity. Its unique Chemical Abstracts Service (CAS) registry number is 164656-23-9. This precise chemical identity distinguishes it from Finasteride, which only inhibits the type II isoenzyme, making Dutasteride theoretically more effective at lowering total DHT levels. The drug is typically administered orally in capsule form, usually once daily, due to its extremely long half-life of approximately five weeks, which allows for sustained therapeutic effects even after discontinuation of therapy.
Beyond urology, Dutasteride has gained attention in dermatology for managing male pattern baldness, offering an alternative when standard treatments fail. However, its use requires careful medical supervision due to potential side effects, including decreased libido, erectile dysfunction, and gynecomastia. Furthermore, it is contraindicated for women who are or may become pregnant because of the risk of causing abnormalities in a male fetus if absorbed through skin contact with crushed capsules. Regulatory agencies worldwide, including the FDA, have approved Dutasteride for specific indications, emphasizing its role as a second-line therapy for BPH or a specialized option for hair loss. Continuous monitoring of prostate-specific antigen (PSA) levels is essential during treatment, as the drug can artificially lower PSA readings by up to 50%, potentially masking early signs of prostate cancer. Overall, Dutasteride represents a significant advancement in endocrine-modulating therapies, balancing efficacy against the need for rigorous safety protocols.